Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2016 Jun;68(6):753–762. doi: 10.1002/acr.22752

Table 4.

Hazard ratios for cause-specific mortality for women with incident RA by serologic phenotype compared to women without RA in the Nurses’ Health Study (1976–2012)*

Cancer mortality
Cardiovascular mortality
Respiratory mortality
Age-adjusted HR (95% CI) Multivariable HR (95% CI) Age-adjusted HR (95% CI) Multivariable HR (95% CI) Age-adjusted HR (95% CI) Multivariable HR (95% CI)
All RA
 No RA 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 RA 1.00 (0.80–1.25) 0.93 (0.74–1.15) 1.49 (1.18–1.89) 1.45 (1.14–1.83) 2.57 (1.91–3.48) 2.06 (1.51–2.80)
Seropositive RA
 No RA 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 RA 0.95 (0.71–1.26) 0.86 (0.65–1.15) 1.39 (1.02–1.90) 1.41 (1.03–1.93) 3.55 (2.55–4.95) 2.67 (1.89–3.77)
Seronegative RA
 No RA 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 RA 1.01 (0.72–1.42) 0.96 (0.68–1.35) 1.55 (1.08–2.21) 1.41 (0.98–2.02) 1.09 (0.54–2.19) 0.98 (0.49–1.99)
*

RA = rheumatoid arthritis; HR = hazard ratio; 95% CI = 95% confidence interval.

Model adjusted for age, questionnaire cycle, census-tract family income (<$40,000 or ≥$40,000 per year), body mass index (<18.5, 18.5–24.9, 25–29.9, or ≥30 kg/m2), cigarette smoking (never–10, 10.1–20, or >20 pack-years), postmenopausal hormone use (premenopausal, postmenopausal: never postmenopausal hormone use, postmenopausal: past postmenopausal hormone use, or postmenopausal: current postmenopausal hormone use), moderate to vigorous physical activity (0, 0.01–0.99, 1.00–3.49, 3.50–5.99, or ≥6 hours per week), cumulative average of Alternate Healthy Eating Index excluding alcohol component (quintiles), alcohol consumption (0, 0.1–4.9, 5.0–14.9, or ≥15.0 gm/day), cardiovascular disease (yes/ no), and aspirin use (yes/no). Covariates were updated up to death, end of study period, censor, or loss to follow-up, whichever came first.